Korean Venture Preps First Ovarian Cancer Cell Therapy
This article was originally published in PharmAsia News
In another notable sign of progress in South Korea’s cell therapy space, a domestic research team has received approval to begin the country’s first clinical trial with an immunotherapy to treat epithelial ovarian cancer, which has the highest mortality rate among female cancer types and is usually discovered only at the advanced stage.
You may also be interested in...
Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll on the Korean firm and partner Evolus as they face a 10-year ban on imports of their product to the US.